We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.2B
$128M 9.13%
3,316,523
+840,251
+34% +$38M
TSRO
2
DELISTED
TESARO, Inc.
TSRO
$92.5M 6.58%
687,993
+5,578
+0.8% +$704K
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$86M 6.11%
17,296,672
+3,180,028
+23% +$22M
SRPT icon
4
Sarepta Therapeutics
SRPT
$2.19B
$76M 5.4%
2,769,829
-625,407
-18% -$25.1M
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
$61.9M 4.4%
692,281
+20,833
+3% +$1.58M
TVTX icon
6
Travere Therapeutics
TVTX
$5.89B
$50.9M 3.62%
2,687,412
+240,930
+10% +$4.93M
NXTM
7
DELISTED
NxStage Medical Inc.
NXTM
$50.5M 3.59%
1,927,989
+258,286
+15% +$6.39M
XNCR icon
8
Xencor
XNCR
$1.77B
$47M 3.34%
1,785,018
+288,789
+19% +$6.94M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$45.2M 3.22%
3,128,978
+794,810
+34% +$14M
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$39.5M 2.81%
498,198
-46,572
-9% -$3.38M
ACRS icon
11
Aclaris Therapeutics
ACRS
$814M
$34.2M 2.43%
1,260,847
+830,847
+193% +$21.2M
ARDX icon
12
Ardelyx
ARDX
$878M
$26.1M 1.85%
1,836,196
+778,939
+74% +$11.1M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$4.24B
$24.8M 1.76%
3,567,553
– –
RGNX icon
14
Regenxbio
RGNX
$525M
$23.8M 1.69%
1,282,286
– –
CLCD
15
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$23.3M 1.66%
641,364
+89,334
+16% +$3.16M
LJPC
16
DELISTED
La Jolla Pharmaceutical Company
LJPC
$23.1M 1.64%
1,319,274
-4,050
-0.3% -$77.6K
AVXS
17
DELISTED
AveXis, Inc. Common Stock
AVXS
$22.6M 1.61%
473,531
+283,531
+149% +$15.2M
DBVT
18
DBV Technologies
DBVT
$739M
$21.5M 1.53%
61,064
+4,737
+8% +$1.7M
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$20.6M 1.47%
+304,531
New +$18.7M
VBIV
20
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$20.4M 1.45%
218,861
+116,913
+115% +$11.2M
WVE icon
21
Wave Life Sciences
WVE
$879M
$18.1M 1.29%
665,198
-18,250
-3% -$594K
ANIP icon
22
ANI Pharmaceuticals
ANIP
$1.66B
$16.2M 1.15%
267,100
+255,539
+2,210% +$15.6M
XLRN
23
DELISTED
Acceleron Pharma
XLRN
$15.8M 1.13%
619,987
+30,097
+5% +$954K
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.7M 1.04%
1,322,994
-50,290
-4% -$473K
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
$14.4M 1.03%
1,388,240
+24,529
+2% +$270K
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.